Emerging Therapies

Section Editors: Marc Fisher, MD, and Antoni Dávalos, MD

Carotid Endarterectomy for Asymptomatic Carotid Stenosis
Asymptomatic Carotid Surgery Trial

P.M. Rothwell, MD, PhD, FRCP; L.B. Goldstein, MD

Effective prevention is inarguably the best option for reducing the individual and societal burden of stroke. For each patient, clinicians balance the benefits of a given preventive therapy against its associated risks and costs. Where possible, these assessments should be based on the results of randomized clinical trials. Carotid endarterectomy (CEA), the most-commonly used surgical procedure to prevent stroke, has been subjected to several randomized trials. These underlie evidence-based guideline and consensus statements providing recommendations for its use.1–7 The evidence base for endarterectomy for symptomatic stenosis is considerable,8,9 but guidelines on surgery for asymptomatic stenosis have been largely based on the results of the Asymptomatic Carotid Atherosclerosis Study (ACAS)10 in conjunction with other smaller trials.11,12 Guidance differs from endorsement of the operation for selected patients (eg, based on patient age, life expectancy, concomitant illnesses, etc.) with varying degrees of asymptomatic stenosis (generally either 60% to 99% or 80% to 99%) in whom the procedure can be performed with low (ie, <3%) complication rates to advising that endarterectomy not be performed in patients without referable symptoms.

ACAS reported a 47% relative reduction in the risk of ipsilateral stroke and perioperative death in patients randomized to surgery despite a 5-year risk of ipsilateral stroke without the operation of only 11%.10 The results led to major increases in rates of endarterectomy for asymptomatic stenosis in some countries, most notably the United States. Of the approximate 150,000 endarterectomies performed in the United States each year, at least half are done for stenoses that have never been symptomatic.13 In contrast, the ACAS results had little effect on endarterectomy rates in other countries such as the United Kingdom, where it was felt that the benefit (it was estimated that 40 operations were needed to prevent 1 disabling or fatal stroke after 5 years) did not justify the cost.

There was also concern that the very low operative risks in ACAS (excluding complications of angiography: 1.5%, 95% CI, 0.6% to 2.4% for stroke and death; and 0.14%, 95% CI, 0% to 0.4%, for death) could not be matched in routine clinical practice. ACAS only accepted surgeons with an excellent safety record, rejecting 40% of initial applicants and subsequently barring from further participation some surgeons who had adverse operative outcomes during the trial.14 Figure 1 compares the operative risks in ACAS with the results of a meta-analysis of the 46 surgical case series that published operative risks for asymptomatic stenosis during ACAS and the 5 years after publication.15 Operative mortality was 8× higher than in ACAS (1.11% versus 0.14%; P=0.01), and the risk of stroke and death was ∼3× higher among comparable studies in which outcome was assessed by a neurologist (4.3% versus 1.5%; P<0.001). Even after community-wide performance measurement and feedback, the overall risk for stroke or death after endarterectomy performed for asymptomatic stenosis in 10 US states was 3.8% (including 1% mortality).16 Therefore, the degree to which the ACAS results can be generalized to routine clinical practice remained uncertain. Results of the largest randomized trial of endarterectomy for asymptomatic stenosis, the Medical Research Council Asymptomatic Carotid Surgery Trial (ACST), have now been published.17 How will these results affect current practice recommendations?

Between 1993 and 2003, ACST randomized 3,120 patients with >60% mainly asymptomatic carotid stenosis (12% had symptoms at least 6 months previously) to immediate endarterectomy plus medical treatment versus medical treatment alone or until the operation became necessary.17 Surgeons were required to provide evidence of an operative risk of ≤6% for their last 50 patients having an endarterectomy for asymptomatic stenosis, but none were excluded on the basis of his/her operative risk during the trial. Selection of patients was based on the “Uncertainty Principle,” with very few...
FIGURE 1. The overall results of a meta-analysis of the operative risk of death (top) from all studies published between 1990 and 2000 inclusive that reported risks of CEA for asymptomatic stenosis and the operative risk of stroke and death in those studies in which outcome was assessed by a neurologist (bottom) compared with the same risks in ACAS.

FIGURE 2. The effect of endarterectomy for asymptomatic carotid stenosis on the risk of any stroke and operative death by sex in ACST and ACAS. is very low poststenotic flow associated with distal narrowing or collapse of the ICA. This situation is paradoxically associated with a low risk of stroke during medical treatment in symptomatic and asymptomatic patients and no clear benefit from endarterectomy (at least in symptomatic cases). The prevalence of near-occlusions during angiography increases with degree of stenosis, as determined by the method used in the European Carotid Surgery Trial (ECST); the North American Symptomatic Carotid Endarterectomy Trial method is not applicable. In the ECST, the proportion of near-occlusions was 0.6% at 60% to 69% stenosis, 2.3% at 70% to 79% stenosis, 9.2% at 80% to 89% stenosis, and 29.5% at 90% to 99% stenosis. In the pooled analysis of the randomized trials of endarterectomy for symptomatic carotid stenosis, the higher proportion of near-occlusions in the upper deciles of stenoses diluted the benefit of endarterectomy, and a clear increase in benefit with degrees of stenosis between 70% and 99% was only apparent when near-occlusions were analyzed separately.

Apart from replicating the results of ACAS in a more pragmatic setting, what else have the results of ACST added? In ACAS, there was a nonsignificant (P = 0.26) 2.7% reduction in the absolute risk of disabling or fatal stroke with surgery. ACST reported a statistically significant (P = 0.004) 2.5% (95% CI, 0.8 to 4.3%) absolute reduction. This observation is important because CEA is a potentially dangerous intervention, and having a precise assessment of its benefits in terms of those outcomes that are of most importance to patients is essential before surgery is recommended to otherwise healthy asymptomatic individuals. ACST has provided this evidence (although the number needed to treat to prevent 1 disabling or fatal stroke after 5 years remains ≈ 40).

In contrast to the results of randomized trials of endarterectomy for symptomatic stenosis, neither ACST nor ACAS showed increasing benefit from surgery with increasing degree of stenosis within the 60% to 99% range. This counterintuitive observation was assumed to be attributable to a lack of statistical power in ACAS but cannot be dismissed with the additional data provided by ACST. Part of the explanation may be that measurement of the exact degree of stenosis is less accurate with Doppler ultrasound scanning than with catheter angiography. For example, neither ACAS nor ACST identified near-occlusions (situations where there
whether there is any worthwhile benefit at all in women. Subgroup analyses can be unreliable, and overall benefit from surgery might well accrue in women with longer follow-up, as is planned for the ACST, but current evidence does not appear to justify the high rates of CEA for asymptomatic stenosis in women in some countries.

Science is based on replication, and ACST largely supports and extends the results of ACAS, showing a small but definite reduction in the risk of disabling or fatal stroke with surgery. The study adds to the body of data on which clinical and policy decisions regarding the potential usefulness of the procedure can be based. Clinicians and policy makers will need to determine whether or not changes in practices and recommendations are warranted.

References


Carotid Endarterectomy for Asymptomatic Carotid Stenosis: Asymptomatic Carotid Surgery Trial

P.M. Rothwell and L.B. Goldstein

*Stroke*. 2004;35:2425-2427; originally published online August 26, 2004;
doi: 10.1161/01.STR.0000141706.50170.a7

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/35/10/2425

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/